Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress
October 31 2014 - 8:30AM
Business Wire
Celgene Corporation (NASDAQ:CELG) plans to present at two
upcoming investor conferences, where Celgene management will
provide an overview of the Company, and at the 56th American
Society of Hematology (ASH) annual meeting in December. The
conferences and ASH event will be webcast live and the webcast will
be available in the Investor Relations section of the Company’s
website at www.celgene.com.
Tuesday, November 11, 2014, Celgene will
present at the Credit Suisse Healthcare Conference in Phoenix at 3
pm ET
Tuesday, December 2, 2014, Celgene will
present at the Deutsche Bank BioFEST Conference in Boston at 3:25
pm ET
Sunday, December 7, 2014, Celgene will
present at the American Society of Hematology at in San Francisco
11:00 p.m. ET
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of novel therapies
for the treatment of cancer and inflammatory diseases through gene
and protein regulation. For more information, please visit
www.celgene.com. Follow us on Twitter @Celgene as well.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
Celgene Corporation Celgene CorporationPatrick E. Flanigan III,
908-673-9969VP, Investor RelationsorBrian Gill, 908-673-9530VP,
Corporate Communications
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2024 to May 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From May 2023 to May 2024